Prescription drug costs for NHS rise by 8% to £10.4bn in England
The annual prescription cost report by the UK’s National Health Services (NHS) has revealed that the total cost of dispensed …
FDA committee recommends AstraZeneca and Sanofi’s RSV prophylactic nirsevimab
A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has voted unanimously in favour of AstraZeneca's and Sanofi’s respiratory …
Novaliq’s dry eye disease therapy receives US FDA approval
Biopharmaceutical company Novaliq has received approval from the US Food and Drug Administration (FDA) for VEVYE (cyclosporine ophthalmic solution) 0.1% …
Upstream Bio raises funds to advance clinical development of UPB-101
Clinical-stage biotech company Upstream Bio has raised $200m in a Series B financing round to advance its UPB-101 to treat …
Bristol Myers Squibb gains FDA approval for production at new facility
The US Food and Drug Administration (FDA) has granted approval to commence commercial production at Bristol Myers Squibb’s new advanced …
China grants EUA to Covid-19 vaccine against XBB descendent lineages
WestVac Biopharma has announced that the Chinese authorities have granted emergency use authorisation (EUA) for coviccine trivalent XBB.1.5-recombinant Covid-19 trivalent …
The challenges of clinical data management: Can consent management software help?
Clinical data management (CDM) is one of the most critical aspects of clinical research. Trial data must be accurate to …
Who’s hiring who? Hiring activity in the Asia-Pacific pharma industry increased by 2% in Q1 2023
The Asia-Pacific pharma industry experienced a 2% rise in new job postings in Q1 2023 compared with the previous quarter, …
Rocket Pharmaceuticals’ RP-A601 receives FDA designations
Rocket Pharmaceuticals has received fast track and orphan drug designations for RP-A601 from the US Food and Drug Administration (FDA) …
Astellas Pharma signs licence deal with Kate Therapeutics for KT430
Astellas Pharma (Astellas) has entered an exclusive licence deal with Kate Therapeutics (KateTx) to develop and commercialise KT430. KateTx will receive …
4DMT’s CF gene therapy posts early cues for improving patient outcomes
The use of 4D Molecular Therapeutics’ (4DMT) aerosolised gene therapy 4D-710 has improved the quality-of-life and spirometry-measured outcomes in three …
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as …
GenScript ProBio and CCS partner for cell and gene therapies development
GenScript ProBio has collaborated with the New York Blood Center Enterprises’ business unit, called Comprehensive Cell Solutions (CCS), to accelerate …
UK’s MHRA expands approval for Merz Therapeutics’ XEOMIN
The UK’s medicines and healthcare products regulatory agency (MHRA) has granted approval for a new indication for Merz Therapeutics’ XEOMIN …
Mendus and NorthX to establish cell therapy manufacturing unit
Mendus has entered an alliance with NorthX Biologics to co-establish a cell therapy manufacturing unit for its lead asset, vididencel, …